Primary packaging container considerations for GLP-1-based drugs
Download the whitepaper to discover primary packaging container considerations for GLP-1-based drugs!
The development of glucagon-like peptide-1 (GLP-1) drugs for type 2 diabetes and obesity has brought hope to patients in improving their health and quality of life. The new molecular entities in clinical trials may bring even better treatments for these and other diseases. Although some of these drugs come in oral dosage form, most are administered by subcutaneous injection. The primary container for injectable drugs is crucial to maintaining drug safety and efficacy through filling, storage, and administration.
Read the whitepaper now and explore trends related to GLP-1-type pharmaceuticals and considerations for fill-and-finish and primary packaging containers!
This article was initially published in Manufacturing Chemist in March 2024.
The development of glucagon-like peptide-1 (GLP-1) drugs for type 2 diabetes and obesity has brought hope to patients in improving their health and quality of life. The new molecular entities in clinical trials may bring even better treatments for these and other diseases. Although some of these drugs come in oral dosage form, most are administered by subcutaneous injection. The primary container for injectable drugs is crucial to maintaining drug safety and efficacy through filling, storage, and administration.
Read the whitepaper now and explore trends related to GLP-1-type pharmaceuticals and considerations for fill-and-finish and primary packaging containers!
This article was initially published in Manufacturing Chemist in March 2024.
